Hydrocodone Conjugates Abuse Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid analgesics, such as hydrocodone, pose a high risk of abuse and addiction due to their rapid action and ease of misuse, leading to unintended addiction and social health issues, with existing abuse-resistant formulations failing to effectively mitigate these risks.
Innovation Solution
The development of covalent conjugates of hydrocodone with aryl carboxylic acids, such as phenylethanoic, phenylpropanoic, and phenylpropenoic acids, which require enzymatic or metabolic breakdown for release, providing a slow and controlled delivery of the active drug, thereby resisting abuse through routes like injection and snorting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydrocodone is administered rapidly or in immediate-release form, then pain relief efficacy is improved, but abuse potential and addiction risk increase
Solution Approach 1:
The patent applies preliminary action by converting hydrocodone into a prodrug conjugate form that requires metabolic activation. The conjugate is designed to be converted into active hydrocodone through enzymatic hydrolysis in the body, thereby controlling the timing and rate of active drug release. This preliminary transformation prevents immediate availability of active hydrocodone, reducing abuse potential while maintaining pain relief efficacy through controlled conversion.
Solution Approach 2:
The patent changes the chemical parameter of hydrocodone by conjugating it with various carboxylic acids (benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid). This chemical modification alters the drug's properties, making it resistant to abuse routes like injection and snorting, while the conjugate is designed to hydrolyze and release active hydrocodone at appropriate rates for effective pain management.
2Object-affected harmful factors
If extended-release formulations are used to reduce abuse potential, then abuse resistance is improved, but users can circumvent the release properties through injection or misuse
Solution Approach 1:
The patent fundamentally changes the chemical parameter of hydrocodone by creating covalent conjugates with carboxylic acids. This chemical modification makes the drug resistant to physical and chemical manipulation methods used to circumvent extended-release formulations. The conjugate structure prevents direct injection effectiveness and resists extraction methods, while still allowing controlled metabolic conversion to active hydrocodone through enzymatic hydrolysis in the body.
3Duration of action of moving object
If covalent conjugates are used to control drug release, then sustained release and abuse resistance are improved, but drug complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts the controlling function from complex formulation systems and embeds it directly into the molecular structure of the drug itself. By incorporating the sustained-release mechanism into the covalent conjugate structure, the patent eliminates the need for complex external control systems, polymers, or multi-component formulations. The release control is achieved through the inherent chemical stability and hydrolysis characteristics of the conjugate bond.
4Speed
If immediate-release hydrocodone is administered, then rapid pain relief is achieved, but addiction develops quickly with dose escalation
Solution Approach 1:
The patent applies preliminary action by pre-converting hydrocodone into a stable conjugate form that serves as a prodrug. This preliminary transformation ensures that active hydrocodone is not immediately available upon administration but must first undergo metabolic conversion. The controlled hydrolysis rate provides gradual release of active drug, maintaining adequate pain relief while preventing the rapid spike in blood concentration that triggers euphoria and accelerates addiction development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates offer a sustained release profile, reducing addiction potential, abuse liability, and side effects, while maintaining therapeutic efficacy, and are resistant to physical and chemical manipulation, ensuring safe and controlled drug delivery.
Implementation Method 1
requiring the active hydrocodone to be released through enzymatic or metabolic breakdown of the conjugate in vivo
Implementation Method 2
requiring the active hydrocodone to be released through enzymatic or metabolic breakdown of the conjugate in vivo
Data Source
AI summary
The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.